AstraZeneca and MSD’s Lynparza for ovarian cancer approved in China
AstraZeneca and MSD (also called Merck & Co. in the US and Canada) have secured China’s National Medical Products Administration (NMPA) marketing authorisation of Lynparza (olaparib) for treating